NLS Pharmaceutics AGNASDAQ:NLSP
- LAST PRICE3.4300
- TODAY'S CHANGE (%)0.0650 (1.9316%)
- Bid / Lots3.0000/ 1
- Ask / Lots3.9000/ 1
- Open / Previous Close3.6000 / 3.3650
- Day Range
- 52 Week Range
- Volume64,496
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NLSP |
|---|---|---|
| 09:32 ET | 300 | 3.6 |
| 09:55 ET | 600 | 3.325 |
| 10:47 ET | 800 | 3.4337 |
| 11:05 ET | 1200 | 3.4 |
| 11:39 ET | 125 | 3.5 |
| 12:51 ET | 200 | 3.5 |
| 01:06 ET | 305 | 3.475 |
| 01:08 ET | 3009 | 3.525 |
| 01:09 ET | 9442 | 3.54 |
| 01:11 ET | 6388 | 3.54 |
| 01:13 ET | 5648 | 3.56 |
| 01:15 ET | 5686 | 3.57 |
| 01:26 ET | 100 | 3.54 |
| 01:38 ET | 5436 | 3.52 |
| 01:56 ET | 3979 | 3.53 |
| 01:58 ET | 1900 | 3.45 |
| 02:00 ET | 500 | 3.43 |
| 02:14 ET | 197 | 3.4 |
| 04:00 ET | 654 | 3.43 |
Nov 18, 2024
Nov 4, 2024
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement, from 7:02AM ET on Monday Nov 04, 2024 by Dow Jones
7:02AM ET on Monday Nov 04, 2024 by Dow Jones
Oct 28, 2024
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements, from 7:02AM ET on Monday Oct 28, 2024 by Dow Jones
7:02AM ET on Monday Oct 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NLS Pharmaceutics AG | 6.7M | -0.5x | --- |
Brainstorm Cell Therapeutics Inc | 6.6M | -0.4x | --- |
National Graphite Corp | 6.8M | -2.0x | --- |
Adial Pharmaceuticals Inc | 6.5M | -0.2x | --- |
Transcode Therapeutics Inc | 6.6M | 0.0x | --- |
Edesa Biotech Inc | 6.9M | -1.0x | --- |
Company Information
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.
Contact Information
- Headquarters
- The Circle 6ZUERICH, Switzerland 8058
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Ronald Hafner
- Chief Executive Officer, Director
- Alexander Zwyer
- Chief Financial Officer
- Elena Thyen-Pighin
- Chief Scientific Officer
- Eric Konofal
- Chief Medical Officer and Global Head of Research and Development
- George Apostol
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.53 |
EPS | $-6.72 |
Book Value | $-10.90 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
